Immunoassay-based proteome profiling of 24 pancreatic cancer cell lines

详细信息	查看全文 | 推荐本文 |

• 作者：Mohamed Saiel Saeed Alhamdani^a ; ^{m.alhamdani@dkfz.de} ; Mahmoud Youns^b ; Malte Buchholz^c ; Thomas M. Gress^c ; Marie-Claire Beckers^d ; Daniel Maré ; chal^d ; Andrea Bauer^a ; Christoph Schrö ; der^a ; Jö ; rg D. Hoheisel^a
• 关键词：Antibody microarray ; Pancreatic cancer ; Pancreatic ductal adenocarcinoma ; Pancreatic cancer cell lines ; Oncoproteomics
• 刊名：Journal of Proteomics
• 出版年：2012
• 期刊代码：P37_18743919
• 类别：ch
• 出版时间：27 June, 2012
• 卷：75
• 期：12
• 页码：3747-3759
• 文件大小：849 K

摘要

Pancreatic ductal adenocarcinoma is one of the most deadly forms of cancers, with a mortality that is almost identical to incidence. The inability to predict, detect or diagnose the disease early and its resistance to all current treatment modalities but surgery are the prime challenges to changing the devastating prognosis. Also, relatively little is known about pancreatic carcinogenesis. In order to better understand relevant aspects of pathophysiology, differentiation, and transformation, we analysed the cellular proteomes of 24 pancreatic cancer cell lines and two controls using an antibody microarray that targets 741 cancer-related proteins. In this analysis, 72 distinct disease marker proteins were identified that had not been described before. Additionally, categorizing cancer cells in accordance to their original location (primary tumour, liver metastases, or ascites) was made possible. A comparison of the cells' degree of differentiation (well, moderately, or poorly differentiated) resulted in unique marker sets of high relevance. Last, 187 proteins were differentially expressed in primary versus metastatic cancer cells, of which the majority is functionally related to cellular movement.